New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis.
about
Therapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosisDifferential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranThe treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitationsRisk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational StudiesTrends in the development of oral anticoagulants.Use of over-the-scope clips (OTSC) for hemostasis in gastrointestinal bleeding in patients under antithrombotic therapyBenefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcomeRisk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis.New insights to occult gastrointestinal bleeding: From pathophysiology to therapeutics.Approach to the new oral anticoagulants in family practice: part 1: comparing the options.Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settingsGastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines.ACG Clinical Guideline: Management of Patients With Acute Lower Gastrointestinal Bleeding.Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation.Discovery of Intra-Abdominal Hemorrhage during Hernioplasty in a Patient Taking RivaroxabanComparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.General Practitioners' vitamin K antagonist monitoring is associated with better blood pressure control in patients with hypertension--a cross-sectional database studySystematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants.Amplatzer Cardiac Plug for Stroke Prevention in Patients with Atrial Fibrillation and Bigger Left Atrial Appendix Size.Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia.Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies.Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding.Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.Risk of Gastrointestinal Bleeding Among Dabigatran Users - A Self Controlled Case Series Analysis.Life-threatening bleeding from gastric mucosal angiokeratomas during anticoagulation: A case report of Fabry disease.Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry.Multidisciplinary management strategies for acute non-variceal upper gastrointestinal bleeding.Potential use of NOACs in developing countries: pros and cons.Risk of bleeding associated with interventional musculoskeletal radiology procedures. A comprehensive review of the literature.Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials.Changing paradigms in the management of deep vein thrombosis.Perspective on the use of sulfated polysaccharides from marine organisms as a source of new antithrombotic drugs.Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding.The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use.Beyond warfarin: The advent of new oral anticoagulants.
P2860
Q26774531-361859D3-D28A-4485-8083-F1CE6C433437Q26799710-992734A8-839F-4F84-963E-76E90A99BD5FQ27694601-7A2CE89F-911E-49B4-A9F3-4F73A8A45E6FQ28078747-D231345E-1E5E-4B3F-A73D-2139E8643DBBQ33424198-E14E5996-D5E5-4199-8D89-C32F2B7556CAQ33643981-63813BCE-B9B8-4F76-842D-E81564EAB6CDQ33646770-70AA65D8-1AF3-4551-AD9D-90DB15C9798FQ33760056-672599BB-23F8-4906-8CC5-55A350DE969DQ33876319-BF820337-6903-46A3-9909-DC6BA5831BDAQ34048017-B0820277-A262-4D79-A3F8-B4748D2E15BBQ34497581-3F2BB97E-03CD-426B-AB54-9A52D174CB78Q34604533-3839AB71-C5C2-4C24-88EB-22F17DAED63DQ34667405-E1D157F1-0C9D-4C8C-A912-756108439B96Q34675946-1D65EE90-18CD-47CC-A092-C8D6AAFEBA7FQ35118898-AD730C21-A520-4D49-A585-49409919DEBDQ35540804-65BAD533-057D-4E2C-B1C9-4EEF04C8091BQ35550883-029E2418-5EA9-4AD1-8E03-CD77BD650249Q35550900-FB5564C1-7019-4E86-ADD2-4223DA2F7BD8Q35658610-36C1FC55-4A8D-47BE-9653-4D820D7F90BBQ35798597-D63EEC7C-DB51-4FB3-B47D-E93F7B3B1E76Q36198941-9D0C4AB3-7CE8-4032-B3FC-4A0BC448DE31Q36201247-423B5F86-82F1-46FA-9E70-4EB7F4B063E8Q36472544-CB6BCD72-188D-4B2F-8256-AABC8AC71483Q36571742-D2808225-1ACC-4AE1-9341-DAAF865A09B1Q37030683-26B5C0C8-A9C9-4E3E-85B1-4BC3C452EB99Q37114565-A6139C35-5384-406D-A5A3-43709674A2A0Q37222352-B1A772FD-DAE0-4E18-9A16-EE6E4890633CQ37595293-AACD7D63-A7F4-4E46-B0F1-5E2381C99B5AQ37646681-1CD0A434-969C-4C6A-9CAD-6703A5D4588CQ37715510-017223E6-6AE8-4CA8-9CAA-1F595CB3BF8CQ38166285-FC2A0C55-C37F-4BBB-80D2-FF0C5CAD368FQ38210994-EC08C21F-B16B-4287-AD0A-89417F6A21A0Q38272660-D473D7F8-3972-473E-B30F-B3BD216F1671Q38287155-99F21C5A-1F49-4CD2-A4AA-606CDCED1B44Q38354452-92B50BED-38D8-4FF5-AAA5-D3F7C278C45BQ38429103-72ED0BEB-BF7B-465C-8FE7-687DC748E058Q38467578-7D2BFAC1-62EE-450B-9EB8-F6F0F1908E44Q38597796-666F6FB9-5D4A-4C61-B70B-0E88199E8FF8Q38664920-F6752409-93A9-4960-9F9E-6F4DA141CBBFQ38692411-F918F879-10AA-47F3-802E-E8B6ACABE91E
P2860
New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
New oral anticoagulants increa ...... atic review and meta-analysis.
@ast
New oral anticoagulants increa ...... atic review and meta-analysis.
@en
New oral anticoagulants increa ...... atic review and meta-analysis.
@nl
type
label
New oral anticoagulants increa ...... atic review and meta-analysis.
@ast
New oral anticoagulants increa ...... atic review and meta-analysis.
@en
New oral anticoagulants increa ...... atic review and meta-analysis.
@nl
prefLabel
New oral anticoagulants increa ...... atic review and meta-analysis.
@ast
New oral anticoagulants increa ...... atic review and meta-analysis.
@en
New oral anticoagulants increa ...... atic review and meta-analysis.
@nl
P2093
P1433
P1476
New oral anticoagulants increa ...... atic review and meta-analysis.
@en
P2093
Eric T T L Tjwa
I Lisanne Holster
Vera E Valkhoff
P304
105-112.e15
P356
10.1053/J.GASTRO.2013.02.041
P407
P577
2013-03-05T00:00:00Z